☆ 4.1 Article

Linking in vitro–in vivo extrapolations with physiologically based modeling to inform drug and formulation development

BIOPHARMACEUTICS & DRUG DISPOSITION (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Pharmacology & Pharmacy

Model-informed drug development: The mechanistic HSK3486 physiologically based pharmacokinetic model informing dose decisions in clinical trials of specific populations

Miao Zhang et al.

Summary: HSK3486 is a central nervous system inhibitor that has demonstrated superior anesthetic properties compared to propofol. The high liver extraction ratio and limited susceptibility to rifampicin make HSK3486 suitable for a wide range of patients. However, in order to expand its indications, it is crucial to assess the systemic exposure of HSK3486 in specific populations and consider the gene polymorphism of UGT1A9, its main metabolic enzyme. A physiologically based pharmacokinetic model of HSK3486 was developed in 2019 to support model-informed drug development (MIDD) and predict the exposure in different populations. The predicted results showed slight increase in hepatic impairment and elderly patients, no change in severe renal impairment and neonates, and significant decrease in pediatric patients. The model also estimated increased exposure in the obese population and poor metabolizers of UGT1A9. Obesity and genetic polymorphisms are unlikely to result in clinically significant changes in anesthesia at the standard dose in adults.

BIOPHARMACEUTICS & DRUG DISPOSITION (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

In-depth analysis of patterns in selection of different physiologically based pharmacokinetic modeling tools: PartI - Applications and rationale behind the use of open source-code software

Arham Jamaal Rajput et al.

Summary: PBPK applications in the literature show a greater use of non-open source-code (NOSC) software compared to open source-code (OSC) alternatives. Understanding the rationale behind utilizing OSC software is important for PBPK modelers. This analysis aims to determine the impact of OSC software on the rise of PBPK and suggests the inclusion of rationale in future PBPK modeling reports.

BIOPHARMACEUTICS & DRUG DISPOSITION (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Develop adult extrapolation to pediatrics and pediatric dose optimization based on the physiological pharmacokinetic model of azithromycin

Luhua Liang et al.

Summary: Physiologically-based pharmacokinetic (PBPK) models were used to support pediatric dose selection for azithromycin. The models were validated to meet the AAFE<2 standard and the predicted pharmacokinetic parameters correlated well with clinical observations. An age-dependent pediatric organ maturity formula was used to extrapolate the adult model to a pediatric model.

BIOPHARMACEUTICS & DRUG DISPOSITION (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Physiologically-based pharmacokinetic/pharmacodynamic modeling to predict tumor growth inhibition and the efficacious dose of selective estrogen receptor degraders in humans

Anjani Ganti et al.

Summary: GDC-9545 is a potential drug candidate for breast cancer, with improved absorption and metabolism compared to its predecessor GDC-0927. Physiologically-based pharmacokinetic/pharmacodynamic (PBPK-PD) models were developed to understand the relationship between GDC-9545 and GDC-0927 exposure and tumor regression in mice, and these models were used to predict the human efficacious dose. The PBPK-PD methodology presented here can support the development of other drug candidates.

BIOPHARMACEUTICS & DRUG DISPOSITION (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

In-depth analysis of patterns in selection of different physiologically-based pharmacokinetic modeling tools: Part II - Assessment of model reusability and comparison between open and non-open source-code software

Hamza Khaled Abdelmajed Aldibani et al.

Summary: While the reproducibility of models in systems biology and quantitative systems pharmacology has received recent attention, the concept of 'reusability' has been neglected. This study defines 'reusability' in the context of physiologically-based pharmacokinetic (PBPK) models and examines the impact of open source-code versus non-open source-code (NOSC) software on the extent of reusability. The results show that the nature of the source-code significantly influences the external reusability of PBPK models, with NOSC models being more reusable compared to open source-code (OSC) models.

BIOPHARMACEUTICS & DRUG DISPOSITION (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds

Jialin Mao et al.

Summary: The quantitative prediction of human pharmacokinetics using physiologically based pharmacokinetic (PBPK) modeling is crucial for early drug development decisions. Through retrospective analysis of 18 Genentech compounds, the PBPK-IVIVE approach was validated in predicting human PK.

BIOPHARMACEUTICS & DRUG DISPOSITION (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Coming full circle: The potential utility of real-world evidence to discern predictions from a physiologically based pharmacokinetic model

Joseph A. Grillo et al.

Summary: Real world data (RWD) are increasingly important in health care decisions. This study explores the potential use of RWD to assess the clinical consequences of a complex drug-drug interaction predicted from a physiologically based pharmacokinetic model (PBPK). The analysis of a dataset of 896,728 patients with mild to moderate chronic kidney disease and rivaroxaban use found that concurrent use of Pgp-CYP3A inhibitors with rivaroxaban increased the risk of bleeding. This exploratory analysis demonstrates the potential utility of RWD in assessing model-based predictions as part of drug life cycle management.

BIOPHARMACEUTICS & DRUG DISPOSITION (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

In vitro-in vivo extrapolation of bexarotene metabolism in the presence of chronic kidney disease and acute kidney injury in rat using physiologically based pharmacokinetic modeling and extrapolation to human

Mo'tasem M. Alsmadi et al.

Summary: Renal impairment can affect the metabolism and clearance of bexarotene, which is important for cancer patients.

BIOPHARMACEUTICS & DRUG DISPOSITION (2023)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Editorial: Insights in drug metabolism and transport: 2021

Janny Pineiro-Llanes et al.

FRONTIERS IN PHARMACOLOGY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Predicting transporter mediated drug-drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where we are now and the way forward

Gautam Vijaywargi et al.

Summary: The use of physiologically-based pharmacokinetic (PBPK) modeling in evaluating metabolic drug-drug interactions is well-documented, but its application in predicting transporter-mediated drug-drug interactions (tDDI) is limited. This is due to the lack of accurate transporter tissue expression levels, reliable in vitro to in vivo extrapolation methods, specific probe substrates, and understanding of inhibition/induction mechanisms. Despite these challenges, advancements in in vitro to in vivo extrapolation methods have enabled accurate predictions of tDDI. Furthermore, regulatory authorities are encouraging the extrapolation of tDDI predictions to special and diseased populations. This review summarizes the current state-of-the-art in tDDI predictions, including the use of static and dynamic PBPK models and the availability of transporter abundance data in special and diseased populations.

BIOPHARMACEUTICS & DRUG DISPOSITION (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms

Eman El-Khateeb et al.

Summary: The study analyzes the advancement of PBPK modeling and simulation over the last 20 years, showing a significant growth rate and a preference for commercial specialized PBPK platforms. The major applications include study design, predicting formulation effects, and metabolic drug-drug interactions, which have increased in proportion over the years.

BIOPHARMACEUTICS & DRUG DISPOSITION (2021)

添加到收藏夹

Article Chemistry, Medicinal

Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization

Jasleen K. Sodhi et al.

Summary: Development of new chemical entities is costly, time-consuming, and has a low success rate. Accurate prediction of hepatic clearance is critical for lead optimization, with in vitro to in vivo extrapolation (IVIVE) being the most commonly employed methodology. This manuscript reviews common in vitro techniques used to predict hepatic clearance as well as current challenges and recent theoretical advancements in IVIVE.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology

Xinyuan Zhang et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2020)

添加到收藏夹

Review Medicine, Research & Experimental

Emerging Role of Organ-on-a-Chip Technologies in Quantitative Clinical Pharmacology Evaluation

Nina Isoherranen et al.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)

添加到收藏夹

Article Chemistry, Medicinal

Integrating Drug- and Formulation-Related Properties With Gastrointestinal Tract Variability Using a Product-Specific Particle Size Approach: Case Example Ibuprofen

Rodrigo Cristofoletti et al.

JOURNAL OF PHARMACEUTICAL SCIENCES (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence

Amin Rostami-Hodjegan

CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug

Shriram M. Pathak et al.

MOLECULAR PHARMACEUTICS (2017)

添加到收藏夹

Review Pharmacology & Pharmacy

ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport-Mediated PK and DDIs in Humans

M. J. Zamek-Gliszczynski et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)

添加到收藏夹

Review Pharmacology & Pharmacy

A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of 'Bottom-Up' vs 'Top-Down' Recognition of Covariates

Masoud Jamei et al.

DRUG METABOLISM AND PHARMACOKINETICS (2009)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

Amin Rostami-Hodjegan et al.

NATURE REVIEWS DRUG DISCOVERY (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.